» Articles » PMID: 20656212

Immunosenescence and Cancer

Overview
Specialty Hematology
Date 2010 Jul 27
PMID 20656212
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Age is a major risk factor for many cancers. Although this is usually viewed in the context of the cell biology, we argue here that age-associated changes to immunity may also contribute to the age-associated increasing incidence of most cancers. This is because cancers are immunogenic (at least initially), and the immune system can and does protect against tumourigenesis. However, immune competence tends to decrease with age, a phenomenon loosely termed "immunosenescence", implying that decreased immunosurveillance against cancer could also contribute to increased disease in the elderly. This review weighs some of the evidence for and against this possibility.

Citing Articles

An in-depth understanding of the role and mechanisms of T cells in immune organ aging and age-related diseases.

Xu Y, Wang Z, Li S, Su J, Gao L, Ou J Sci China Life Sci. 2024; 68(2):328-353.

PMID: 39231902 DOI: 10.1007/s11427-024-2695-x.


Integrative analysis of aging-related genes reveals CEBPA as a novel therapeutic target in non-small cell lung cancer.

Zhu J, Zhu X, Shi C, Li Q, Jiang Y, Chen X Cancer Cell Int. 2024; 24(1):267.

PMID: 39068458 PMC: 11282817. DOI: 10.1186/s12935-024-03457-4.


Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients.

Ohba K, Nakanishi H, Kawada K, Nakamura Y, Mitsunari K, Matsuo T Jpn J Clin Oncol. 2024; 54(7):827-832.

PMID: 38651176 PMC: 11228832. DOI: 10.1093/jjco/hyae046.


Tuberculosis and COVID-19 in the elderly: factors driving a higher burden of disease.

Allue-Guardia A, Torrelles J, Sigal A Front Immunol. 2023; 14:1250198.

PMID: 37841265 PMC: 10569613. DOI: 10.3389/fimmu.2023.1250198.


The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y Onco Targets Ther. 2022; 15:1321-1330.

PMID: 36388155 PMC: 9645692. DOI: 10.2147/OTT.S389138.